IPAB throws out Indian Vega trademarks
The Intellectual Property Appellate Board in Chennai has cancelled two trademarks associated with versions of Viagra.
UK Appeals Court upholds Teva’s Copaxone patent
The Court of Appeal for England and Wales has upheld the Patent Court’s decision that Teva Pharmaceutical Industries’ UK patent 762,888, relating to the multiple sclerosis drug Copaxone, is valid.
US court rules Teva patent invalid
A US court has ruled that an Israeli company’s patent for a multiple sclerosis (MS) drug is invalid, paving the way for rivals to market a generic version.
Novozymes loses appeal in DuPont patent war
A US court has upheld a decision ruling that a continuation patent filed by a bio-tech company is invalid.
FTC welcomes Supreme Court 'pay-for-delay' ruling
The chair of the FTC has said it will continue to challenge pay-for-delay court settlements in the pharmaceutical industry and has hailed a Supreme Court ruling as a victory for consumers.
Ability to settle cases influences generic patent challenges, study finds
A white paper suggests that patent case settlements between originator pharmaceutical companies and their generic competitors may be beneficial to drug consumers.
USPTO announces departure of general counsel
The chief legal officer at the United States Patent and Trademark Office has announced he will be leaving.
Leahy demands Myriad “march-in rights”
Senator Patrick Leahy has urged the US National Institutes of Health to force Myriad Genetics to license its patents directed to tests for breast and ovarian cancer.
Ipsen announces acquisition of research partner Syntaxin
On July 15, French pharmaceutical company Ipsen announced it has closed the acquisition of life sciences company and research partner Syntaxin.
US appeals court refuses Arzerra rehearing
Biotechnology company Genmab A/S announced on July 15 that the US Court of Appeals for the Federal Circuit has refused a request to rehear a case related to its Arzerra product.
